Physical Therapy in Women With Interstitial Cystitis (IC03)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
University of Pennsylvania
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00733603
First received: August 12, 2008
Last updated: January 12, 2010
Last verified: January 2010
  Purpose

There are many different treatments that doctors recommend for patients with IC/PBS. Only a few research studies have been done to evaluate treatments given to patients. Treatment choices can be of two types: drug therapy and non-drug therapy. The two treatments used in this study will be of the non-drug therapy type. One of the treatments being used in this study is called Myofascial Tissue Manipulation. This is a kind of physical therapy that is designed to work on specific muscles and tissue layers in a particular part of the body. In this study, this treatment will focus on the areas around the pelvis and the pelvic floor. The treatment will involve the physical therapist's use of hands and fingers to target specific muscles and tissues located within your pelvis, rectum, and/or vagina (the pelvic floor) as well as muscles and layers of tissue in your abdomen and legs. The other treatment being used in this study is Global Therapeutic Massage. This treatment involves the physical therapist's use of classic Western body massage techniques on the muscles of your arms, legs, hands, neck, shoulders, back, stomach, buttocks, and feet to create an overall feeling of well being.

The purpose of this research study is to find out if Pelvic Physical Therapy is safe and effective on treating symptoms in women with interstitial cystitis as compared to a full body therapeutic massage. This study will also measure the lasting effects of the treatment up to 3 months after your last study treatment.


Condition Intervention
Interstitial Cystitis
Painful Bladder Syndrome
Other: Global Therapeutic Massages (GTM)
Other: Myofascial Tissue Manipulation (MTM)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Single-Blinded Randomized Multi-Center Trial to Evaluate the Efficacy and Durability of Myofascial Tissue Manipulation in Women With Interstitial Cystitis/Painful Bladder Syndrome

Resource links provided by NLM:


Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
  • To determine the efficacy, safety and tolerability of Myofascial Tissue Manipulation (MTM) in women with IC/PBS, as compared to Global Therapeutic Massage (GTM). [ Time Frame: 12 Weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To determine the durability of Myofascial Tissue Manipulation (MTM) in women with IC/PBS, as compared to Global Therapeutic Massage (GTM). [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 88
Study Start Date: June 2008
Estimated Study Completion Date: May 2009
Estimated Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Sham Comparator: 1
Global Therapeutic Massage (GTM)
Other: Global Therapeutic Massages (GTM)
Non-specific somatic treatment with full-body Western massage.
Active Comparator: 2
Myofascial Tissue Manipulation (MTM)
Other: Myofascial Tissue Manipulation (MTM)
Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant has signed and dated the appropriate Informed Consent document.
  • Female participant is ≥ 18 years of age.
  • Currently using an approved method of birth control, or surgically sterile, or of non-child bearing age with no menstrual period for the past year.
  • Participant has a clinical diagnosis of IC/PBS in the opinion of the investigator.
  • Participant with IC/PBS has reported a bladder pain/discomfort score of 3 or greater on a 0-10 Likert scale over the previous four weeks. This bladder pain/discomfort criterion must be met at each of the two baseline screening visits as reported by the participant.
  • Participant with IC/PBS has reported a symptom score of abnormal urinary frequency of 3 or greater on a 0-10 Likert scale over the previous four weeks. This frequency criterion must be met at each of the two baseline screening visits, as reported by the participant.
  • Participant has had symptoms of discomfort or pain in the pelvic region for at least a three (3) month period within the last six (6) months.
  • Current symptoms have been present for less than 3 years. If similar symptoms were present in the past, they must have been completely resolved for at least one year prior to onset of current symptoms.
  • Participant has previously undergone at least one course of therapy (other than physical therapy) for her symptoms.
  • Presence of tenderness/pain to palpation found by the physician in one of the pelvic floor musculature domains during the first baseline screening visit physical examination which are confirmed by the physical therapist at screening visit 2. Presence of tenderness/pain is defined as a mild, moderate or severe finding by the physician at visit 1 and physical therapist at visit 2. The pelvic floor musculature domains are defined as: anterior or posterior levator muscles, obturator internus muscles and urogenital diaphragm (bulbospongiosus, superficial transverse perinei, ischiocavernosus, central tendon/perineal body). The assessment of tenderness/pain at Visits 1 and 2 do not need to be identical in severity or location in order for the participant to be eligible.

Exclusion Criteria:

  • Participant has relevant, painful scars on lower abdominal wall that, in the opinion of the study physician or physical therapist, is unlikely to respond to physical therapy without adjuvant therapy such as injection /needling.
  • A positive urine culture (defined as >100,000 CFU/ml) is exclusionary. A negative urine culture within 1 month of study enrollment is acceptable.
  • Participant is unable to tolerate insertion of one or two vaginal examining fingers (e.g. vulvar allodynia), or one rectal examining finger.
  • Participant had prior course of physical therapy that included manual therapy with connective tissue manipulation by physical therapist for same symptoms. Prior treatment by therapist with biofeedback, electrical stimulation, or pelvic floor exercises is not exclusionary.
  • Participant has relevant neurologic disorder that affects bladder and/or neuromuscular function in the opinion of the investigator.
  • Participant has active urethral or ureteral calculi, urethral diverticulum.
  • Participant has a history of pelvic radiation therapy, tuberculous cystitis, bladder cancer, carcinoma in situ, or urethral cancer.
  • Participant has/reports any severe debilitating or urgent concurrent medical condition.
  • Participant has a potentially significant pelvic pathology or abnormalities on examination or prior imaging, including prolapse beyond the hymenal ring, pelvic mass, etc. that could cause or contribute to the clinical symptoms or require treatment.
  • Participant is unlikely to be compliant due to unmanaged medical or psychological condition, including neurological, psychological or speech /language problems that will interfere with her ability to complete the study.
  • Participant has an imminent change in residence or other social factors that could compromise compliance with the protocol.
  • Pregnancy or refusal of medically approved/reliable birth control in women of child-bearing potential.
  • Participant has pain, frequency, urgency symptoms present only during menses.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00733603

Locations
United States, California
Univeristy of California San Diego
San Diego, California, United States, 92093
Stanford University Medical center
Stanford, California, United States, 94305
United States, Illinois
Loyola University Medical Center
Maywood, Illinois, United States, 60153
United States, Iowa
University of Iowa Hospitals and Clinic
Iowa City, Iowa, United States, 52242
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642
United States, Pennsylvania
University of Pennsylvania Health System
Philadelphia, Pennsylvania, United States, 19104
United States, Washington
University of Washington
Seattle, Washington, United States, 98195
Canada, Ontario
Queen's University
Kingston, Ontario, Canada, K7L2V7
Sponsors and Collaborators
University of Pennsylvania
Investigators
Study Director: LeRoy M Nyberg, MD, PhD NIDDK/NIH
Study Chair: Mary P Fitzgerald, MD Loyola University
Principal Investigator: Richard Landis, PhD University of Pennsylvania
Principal Investigator: Robert Mayer, MD University of Rochester
Principal Investigator: Emily Lukacz, MD University of California, San Diego
Principal Investigator: Kenneth Peters, MD William Beaumont Hospital, Royal Oak, MI
Principal Investigator: Toby Chai, MD University of Maryland
Principal Investigator: Christopher Payne, MD Stanford University
Principal Investigator: Claire Yang, MD University of Washington
Principal Investigator: Phillip Hanno, MD University of Pennsylvania
Principal Investigator: Karl Kreder, MD University of Iowa
Principal Investigator: David Burks, MD Henry Ford Hospital, Detroit
Principal Investigator: Curtis Nickel, MD Queen's University, Ontario, Canada
Study Chair: Harris Foster, MD Yale University
  More Information

No publications provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: LeRoy M. Nyberg, MD, PhD, NIDDK
ClinicalTrials.gov Identifier: NCT00733603     History of Changes
Other Study ID Numbers: ICCRN RCT#3 (IND), U01-DK065209
Study First Received: August 12, 2008
Last Updated: January 12, 2010
Health Authority: United States: NIDDK, NIH
United States: Institutional Review Board
United States: Federal Government
Canada: Research Ethics Board

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Interstitial Cystitis
IC
Painful Bladder Syndrome
PBS
Bladder Pain
Pelvic Pain

Additional relevant MeSH terms:
Cystitis
Pain
Cystitis, Interstitial
Urinary Bladder Diseases
Urologic Diseases
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on July 29, 2014